With ADC’s, due to the specificity of the mAb used, patient cohorts will usually be selected at the Phase I level, with the cancers in the patient expressing the required epitope; examples would be in cancers expressing Her2, or a specific leukemia cell’s epitope. Here, ERBB2 is linked to cancer.